Search

Your search keyword '"Francesca Rini"' showing total 2 results
Start Over Author "Francesca Rini" Publisher blackwell publishing ltd
2 results on '"Francesca Rini"'

1. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study

Author

Antonio Solano, Anna Ludovica Fracanzani, Ferdinando Carlo Sasso, Salvatore Petta, Pia Clara Pafundi, Antonio Craxì, Riccardo Nevola, Barbara Guerrera, Carmine Coppola, Vito Di Marco, Rosa Lombardi, Vincenzo Narciso, Aldo Marrone, Vincenza Calvaruso, Luigi Elio Adinolfi, Luca Rinaldi, Mariarosaria Saturnino, Mauro Giordano, Francesca Rini, Laura Staiano, Graziano Troina, Adinolfi L.E., Petta S., Fracanzani A.L., Nevola R., Coppola C., Narciso V., Rinaldi L., Calvaruso V., Pafundi P.C., Lombardi R., Staiano L., Di Marco V., Solano A., Marrone A., Saturnino M., Rini F., Guerrera B., Troina G., Giordano M., Craxi A., Sasso F.C., Adinolfi, Luigi E, Petta, Salvatore, Fracanzani, Anna L, Nevola, Riccardo, Coppola, Carmine, Narciso, Vincenzo, Rinaldi, Luca, Calvaruso, Vincenza, Pafundi, Pia Clara, Lombardi, Rosa, Staiano, Laura, Di Marco, Vito, Solano, Antonio, Marrone, Aldo, Saturnino, Mariarosaria, Rini, Francesca, Guerrera, Barbara, Troina, Graziano, Giordano, Mauro, Craxì, Antonio, and Sasso, Ferdinando C

Subjects
medicine.medical_specialty, Cirrhosis, endocrine system diseases, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Antiviral Agents, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, chronic hepatiti, Internal medicine, Internal Medicine, medicine, Humans, Glucose homeostasis, Prospective Studies, Prospective cohort study, direct-acting antiviral, business.industry, Incidence, Incidence (epidemiology), nutritional and metabolic diseases, Type 2 Diabetes Mellitus, Hepatitis C, Chronic, medicine.disease, Diabetes Mellitus, Type 2, Case-Control Studies, Relative risk, HCV, Population study, type 2 diabetes, business, cirrhosi
Abstract

Aim HCV infection increases the risk of type 2 diabetes mellitus (T2DM). However, it remains still unclear whether HCV clearance by direct-acting antivirals (DAA) reduces T2DM. Therefore, the effect of HCV eradication on T2DM incidence was assessed. Methods A prospective multicenter case-control study was performed, which included 2,426 HCV patients, 42% of which with liver fibrosis F0-F2 and 58% F3-F4. Study population consisted of a control group including 1099 untreated patients and 1327 cases treated with DAA. T2DM incidence was assessed during a follow-up median period of 30 [IQR: 28-42] months. Risk factors of T2DM were assessed by Cox regression model (Relative risk (RR), Hazard risk (HR), Kaplan-Meier). Insulin sensitivity was evaluated by HOMA and changes by ANOVA for repeated measurements. Factors independently associated with T2DM were assessed by multivariate analysis RESULTS: The absolute incidence of T2DM/1,000 person-years for controls and cases was 28 and 7, respectively (p=0.001). In cases compared to controls, HCV clearance reduced the RR and HR of T2DM by 81% and 75-93% respectively (p = 0.001). It has been calculated that for every 15 patients who obtained HCV clearance one case of T2DM is saved. HCV clearance was associated with a significant reduction in HOMA-IR and HOMA- β and an increase in HOMA-S as assessed in 384 patients before and after HCV clearance. At multivariate analysis, HCV clearance emerged as independently associated with a reduced T2DM risk. Conclusion HCV clearance by DAA treatment reduces T2DM incidence more likely by restoring the HCV-induced alteration of glucose homeostasis mechanisms. This article is protected by copyright. All rights reserved.

Published
2020

2. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy

Author

Calogero Cammà, Vito Di Marco, Francesca Rini, S. Ciminnisi, Vincenza Calvaruso, Rosaria Maria Pipitone, Salvatore Petta, Antonio Craxì, Edoardo G. Giannini, Stefania Grimaudo, Petta S., Rini F., Calvaruso V., Camma C., Ciminnisi S., Di Marco V., Giannini E.G., Grimaudo S., Maria Pipitone R., and Craxi A.

Subjects
Liver Cirrhosis, medicine.medical_specialty, Cirrhosis, Sofosbuvir, Hepatitis C virus, Hepacivirus, medicine.disease_cause, Antiviral Agents, Gastroenterology, Internal medicine, Humans, Medicine, Decompensation, Aminopyrine, Child, CIRRHOSIS, Hepatic encephalopathy, aminopyrine breath test, Breath test, Hepatology, medicine.diagnostic_test, direct antiviral agent, Cumulative dose, business.industry, Hepatitis C, Chronic, medicine.disease, Hepatitis C, Breath Tests, liver function, Liver function, business, DIRECT ANTIVIRAL AGENTS, AMINOPYRINE BREATH TEST, LIVER FUNCTION, medicine.drug, cirrhosi
Abstract

Background & Aims: In patients with hepatitis C virus (HCV)-related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13C-aminopyrine breath test (ABT) to assess whether its changes can predict liver-related outcomes after DAA treatment in patients with HCV cirrhosis. Methods: Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N=22, 44%) or previous decompensation (N=7, 14%) – or Child B cirrhosis (N=21, 42%) eligible for DAA-based antiviral therapy. ABT was performed at baseline and 12weeks after the end of antiviral therapy. Patients received sofosbuvir-based regimens. Results: Aminopyrine breath test was available for all 50 patients at baseline. The 120’ cumulative dose was directly associated at regression analysis only with albumin levels (P=.001). ABT was available at follow-up week 12 for 41 patients (FUW12), all with SVR, and followed for a median of 25.2months (range 12.2-32.1months). Lower Ʌ ABT – defined as changes of 120’ cumulative dose from FUW12 to baseline – (HR 0.97, 95% CI 0.94-0.99; P=.02) and FUW12 hepatic encephalopathy (HR 19.0, 95% CI 1.16-310.3; P=.03) were the only independent predictors of liver events/death at multivariate Cox regression analysis. The AUC of Ʌ ABT was good (0.87, 95% CI 0.75-0.97), with a delta ≥0% well discriminating patients at lower vs patients at higher risk of liver-related events/death (P&nbsp

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results